Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) Restructuring Costs (2023)

Fate Therapeutics' Restructuring Costs history spans 1 years, with the latest figure at $2.0 million for Q1 2023.

  • For Q1 2023, Restructuring Costs changed N/A year-over-year to $2.0 million; the TTM value through Dec 2023 reached $2.0 million, changed N/A, while the annual FY2023 figure was $2.0 million, N/A changed from the prior year.
  • Restructuring Costs reached $2.0 million in Q1 2023 per FATE's latest filing.
  • In the past five years, Restructuring Costs ranged from a high of $2.0 million in Q1 2023 to a low of $2.0 million in Q1 2023.